| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
J Clin Oncol
|
2010
|
14.41
|
|
2
|
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
|
J Clin Oncol
|
2013
|
12.57
|
|
3
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
|
Arch Pathol Lab Med
|
2010
|
4.38
|
|
4
|
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.
|
J Clin Invest
|
2003
|
3.14
|
|
5
|
Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.
|
Arch Pathol Lab Med
|
2009
|
2.97
|
|
6
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
Arch Pathol Lab Med
|
2010
|
2.72
|
|
7
|
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines.
|
Breast Cancer (Auckl)
|
2010
|
2.57
|
|
8
|
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
|
Arch Pathol Lab Med
|
2013
|
2.54
|
|
9
|
Recommendations for improved standardization of immunohistochemistry.
|
Appl Immunohistochem Mol Morphol
|
2007
|
2.24
|
|
10
|
A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
|
Appl Immunohistochem Mol Morphol
|
2007
|
2.15
|
|
11
|
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2006
|
1.70
|
|
12
|
Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry.
|
Appl Immunohistochem Mol Morphol
|
2008
|
1.69
|
|
13
|
The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course.
|
Clin Cancer Res
|
2005
|
1.68
|
|
14
|
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
|
Breast Cancer Res Treat
|
2008
|
1.68
|
|
15
|
Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cells.
|
Am J Pathol
|
2007
|
1.46
|
|
16
|
Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?
|
Diagn Mol Pathol
|
2009
|
1.43
|
|
17
|
Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.
|
J Natl Cancer Inst
|
2012
|
1.42
|
|
18
|
HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
|
Ann Surg Oncol
|
2008
|
1.41
|
|
19
|
Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling.
|
J Biol Chem
|
2008
|
1.30
|
|
20
|
Malignant solitary fibrous tumor: report of 3 cases with unusual features.
|
Appl Immunohistochem Mol Morphol
|
2009
|
1.26
|
|
21
|
Defining the expression pattern of the LGI1 gene in BAC transgenic mice.
|
Mamm Genome
|
2007
|
1.25
|
|
22
|
Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo.
|
Breast Cancer Res Treat
|
2006
|
1.20
|
|
23
|
Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP).
|
J Bone Miner Res
|
2012
|
1.19
|
|
24
|
Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
|
Diagn Mol Pathol
|
2007
|
1.10
|
|
25
|
The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
|
Am J Surg Pathol
|
2005
|
1.05
|
|
26
|
Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes.
|
Genes Chromosomes Cancer
|
2007
|
1.03
|
|
27
|
Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression.
|
Cancer Res
|
2011
|
1.02
|
|
28
|
HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.
|
Mod Pathol
|
2011
|
1.01
|
|
29
|
A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
|
Cancer Invest
|
2010
|
1.00
|
|
30
|
Folate receptor α associated with triple-negative breast cancer and poor prognosis.
|
Arch Pathol Lab Med
|
2013
|
0.98
|
|
31
|
Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry.
|
Mod Pathol
|
2012
|
0.96
|
|
32
|
Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.
|
Breast Cancer (Auckl)
|
2011
|
0.94
|
|
33
|
The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
|
Breast J
|
2007
|
0.94
|
|
34
|
Parathyroid hormone-related Peptide expression in cartilaginous tumors.
|
Clin Orthop Relat Res
|
2002
|
0.94
|
|
35
|
TLE3 as a candidate biomarker of response to taxane therapy.
|
Breast Cancer Res
|
2009
|
0.92
|
|
36
|
GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor.
|
Hum Pathol
|
2012
|
0.91
|
|
37
|
Solitary fibrous tumor of the breast and mammary myofibroblastoma: the same lesion?
|
Breast J
|
2008
|
0.90
|
|
38
|
Analysis of gene expression in mineralized skeletal tissues by laser capture microdissection and RT-PCR.
|
Lab Invest
|
2006
|
0.89
|
|
39
|
HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.
|
Oncologist
|
2009
|
0.89
|
|
40
|
Osteoclastlike giant cell tumor of the salivary gland.
|
Ann Diagn Pathol
|
2007
|
0.89
|
|
41
|
Expression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytes.
|
J Orthop Res
|
2005
|
0.86
|
|
42
|
SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.
|
Clin Orthop Relat Res
|
2007
|
0.84
|
|
43
|
An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanning.
|
J Mol Histol
|
2007
|
0.83
|
|
44
|
Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility study.
|
Appl Immunohistochem Mol Morphol
|
2006
|
0.82
|
|
45
|
Vocal fold healing after laser cordectomy with adjuvant cryotherapy.
|
Laryngoscope
|
2006
|
0.82
|
|
46
|
Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast.
|
Arch Pathol Lab Med
|
2013
|
0.81
|
|
47
|
Predictors of nipple-areolar complex involvement by breast carcinoma: histopathologic analysis of 787 consecutive therapeutic mastectomy specimens.
|
Ann Surg Oncol
|
2011
|
0.80
|
|
48
|
Dual expression of alpha-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of alpha-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas.
|
Mod Pathol
|
2009
|
0.80
|
|
49
|
Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17.
|
Breast Cancer (Auckl)
|
2010
|
0.79
|
|
50
|
A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institution.
|
Breast
|
2006
|
0.78
|
|
51
|
Immunohistochemical evaluation of microphthalmia-associated transcription factor expression in giant cell lesions.
|
Mod Pathol
|
2004
|
0.77
|
|
52
|
Tissue pattern recognition error rates and tumor heterogeneity in gastric cancer.
|
Appl Immunohistochem Mol Morphol
|
2013
|
0.77
|
|
53
|
Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression.
|
J Urol
|
2008
|
0.76
|
|
54
|
A new rabbit monoclonal E-cadherin antibody [EP700Y] shows higher sensitivity than mouse monoclonal E-cadherin [HECD-1] antibody in breast ductal carcinomas and does not stain breast lobular carcinomas.
|
Appl Immunohistochem Mol Morphol
|
2014
|
0.76
|
|
55
|
Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group.
|
Sarcoma
|
2003
|
0.76
|
|
56
|
Expression of androgen receptor and its association with estrogen receptor and androgen receptor downstream proteins in normal/benign breast luminal epithelium.
|
Appl Immunohistochem Mol Morphol
|
2014
|
0.76
|
|
57
|
American Society of Clinical Oncology/College of American Pathologists Human Epidermal Growth Factor Receptor 2 Testing Clinical Practice Guideline Upcoming Modifications: Proof That Clinical Practice Guidelines Are Living Documents.
|
Arch Pathol Lab Med
|
2015
|
0.75
|
|
58
|
A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers.
|
Nutr Cancer
|
2014
|
0.75
|
|
59
|
HER-2 testing in breast cancer.
|
JAMA
|
2004
|
0.75
|
|
60
|
Progress in implementing HER2 testing guidelines.
|
Arch Pathol Lab Med
|
2014
|
0.75
|
|
61
|
Citius, altius, fortius-self-assessment in pathology and laboratory medicine: College of American Pathologists Self-assessment Module Committee.
|
Arch Pathol Lab Med
|
2011
|
0.75
|
|
62
|
Benign inclusion of axillary lymph nodes: report of two cases and literature review.
|
Breast J
|
2009
|
0.75
|
|
63
|
High-resolution immunophenotyping of subcellular compartments in tissue microarrays by enzyme metallography.
|
Appl Immunohistochem Mol Morphol
|
2005
|
0.75
|
|
64
|
Standardization of tissue handling from the OR to the laboratory.
|
AORN J
|
2014
|
0.75
|
|
65
|
Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression.
|
Histopathology
|
2014
|
0.75
|
|
66
|
The role of the indispensable surgical pathologist in treatment planning for breast cancer.
|
Arch Pathol Lab Med
|
2008
|
0.75
|
|
67
|
The unmet clinical need for new molecular genetic markers in the prognosis and therapeutic management of breast cancer.
|
Arch Pathol Lab Med
|
2005
|
0.75
|
|
68
|
HER2 status in bilateral breast cancer.
|
Int J Fertil Womens Med
|
2007
|
0.75
|
|
69
|
[Molecular phenotypes of breast cancer and their clinical application].
|
Zhonghua Bing Li Xue Za Zhi
|
2009
|
0.75
|
|
70
|
Breast and Prostate Cancer in a BRCA2 Carrier.
|
Breast J
|
2012
|
0.75
|